Both the antibody and the soluble OX-40L fusion protein can work with similar potency in the tumor models mentioned here (FIG. 13 and other data not shown), but it is possible that the antibody may have some advantage in the future if it turns out to be less immunogenic and to have a longer-half life in vivo.